Merck KGaA/SFJ's Abituzumab Evaluated For Left-Sided Metastatic Colon Cancer

SFJ Pharmaceuticals has taken on the late-stage clinical development of Merck KGaA's previously stalled MAb abituzumab, sharing the financial risk...

More From BioPortfolio on "Merck KGaA/SFJ's Abituzumab Evaluated For Left-Sided Metastatic Colon Cancer"